Streetbeat News

Revenues

DCTH

Delcath Systems has initiated the commercial use of its HEPZATO KIT for the treatment of metastatic uveal melanoma. This marks a significant milestone for the company as it begins to generate revenue from the product.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:13 pm

SLDB

Solid Biosciences Inc. (NASDAQ:SLDB) has received FDA Orphan Drug Designation for its Duchenne muscular dystrophy gene therapy candidate, SGT-003. The company, which focuses on precision genetic medicines for neuromuscular and cardiac diseases, also received Fast Track Designation last month. Patient dosing for the Phase 1/2 clinical trial of SGT-003 is expected to begin in mid-to-late Q1 2024. SGT-003 features a novel capsid and muscle tropic vector, which may offer improved transduction and muscle resiliency. The Orphan Drug Designation provides benefits such as financial incentives and the potential for seven years of market exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:08 pm

SLGG

Super League (NASDAQ: SLE) reported a record preliminary Q4 revenue of approximately $9.4 million, a 32% increase YoY, and annual revenues of about $25.0 million. The company anticipates profitability in 2024, backed by a record contract and pipeline expansion. Super League's CEO Ann Hand highlighted the company's growth, streamlined operations, and success in immersive 3D experiences on platforms like Roblox, Minecraft, and Fortnite. The company served almost 100 brands in 2023, with significant engagement and media coverage. Super League aims to transition from short-term campaigns to larger, recurring deals with notable clients like Visa, Disney, and Wal-Mart. The company raised $24.8 million and secured a $4.0 million accounts receivable facility, improving its balance sheet for future growth.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:07 pm

APLD

Applied Digital (APLD) has announced that due to delayed delivery of networking components for GPU clusters, the company's revenue and EBITDA for fiscal year 2024 will be below the previously guided range.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:03 pm

BIOR

Biora Therapeutics, Inc. (NASDAQ:BIOR) provided guidance on anticipated milestones for 2024, including the phase 1 study of BT-600, part of the NaviCap platform, aimed at treating ulcerative colitis (UC). The company expects initial phase 1 data in 2-3 months, with a potential phase 1B study in UC patients and a 56-day GLP tox study planned for the second half of 2024. Biora also highlighted progress with its BioJet platform, with ongoing preclinical data generation and potential expansion of pharma collaborations. The NaviCap platform is designed for targeted delivery of therapeutics to the GI tract, and the BioJet platform is for oral delivery of large molecules.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:02 pm

YOU

Four analysts have recently updated their ratings on Clear Secure (NYSE:YOU), with an average 12-month price target of $31.75, up from the previous $24.00. The ratings range from 'Buy' to 'Underweight', with price targets varying from $20.00 to $40.00. Clear Secure has shown strong financial performance with a revenue growth of 38.36%, a net margin of 9.57%, an ROE of 5.65%, and an ROA of 1.43%. The company's debt-to-equity ratio is 0.47, indicating a balanced debt approach.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 1:01 pm

DRVN

Driven Brands Hldgs (NASDAQ:DRVN) received mixed analyst ratings with 2 somewhat bullish and 2 indifferent. Analysts from Morgan Stanley, Piper Sandler, and Goldman Sachs lowered their price targets, reflecting a negative sentiment shift. The average price target is now $19.00, down 15.56% from previous estimates. Driven Brands Hldgs, an automotive services company, shows a positive revenue trend but struggles with profitability and high debt levels. Analysts' actions and ratings are crucial for understanding the company's market position.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 1:00 pm

KR

Analysts have provided mixed ratings for Kroger (NYSE:KR) with an average 12-month price target of $51.8, up from $51.33. Recent actions include maintaining and lowering ratings with price targets ranging from $46 to $55. Kroger's financials show a slight revenue decline, strong net margin, ROE, and ROA, with a healthy debt-to-equity ratio. The company's proposed $25 billion acquisition of Albertsons is pending regulatory approval.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 1:00 pm

BROS

Seven analysts have recently reviewed Dutch Bros (NYSE:BROS), with a mix of bullish and bearish sentiments. The average 12-month price target is $32.86, up from the previous $31.86. Analysts from firms like Stifel, Barclays, Wedbush, and JP Morgan have adjusted their ratings and price targets, reflecting their views on the company's market performance. Dutch Bros has shown strong revenue growth but has below-average net margin, ROE, and ROA, with a conservative debt-to-equity ratio. Analyst ratings are important as they are based on future earnings predictions and company performance analysis.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 1:00 pm

CSR

Centerspace (NYSE:CSR), a REIT, has received mixed analyst ratings over the past three months, with 1 bullish, 1 somewhat bullish, and 2 indifferent. The average 12-month price target is $60.75, down from $61.00. Analysts from RBC Capital and Piper Sandler have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Centerspace's financials show a -1.33% revenue decline as of September 30, 2023, a net margin of 9.55%, ROE of 0.96%, ROA of 0.32%, and a debt-to-equity ratio of 1.31.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 1:00 pm